BR112016015763B8 - pharmaceutical preparation including pyridylaminocetic acid compound, and, use of the same - Google Patents

pharmaceutical preparation including pyridylaminocetic acid compound, and, use of the same

Info

Publication number
BR112016015763B8
BR112016015763B8 BR112016015763A BR112016015763A BR112016015763B8 BR 112016015763 B8 BR112016015763 B8 BR 112016015763B8 BR 112016015763 A BR112016015763 A BR 112016015763A BR 112016015763 A BR112016015763 A BR 112016015763A BR 112016015763 B8 BR112016015763 B8 BR 112016015763B8
Authority
BR
Brazil
Prior art keywords
pharmaceutical preparation
pyridylaminocetic
intraocular pressure
glaucoma
compounds
Prior art date
Application number
BR112016015763A
Other languages
Portuguese (pt)
Other versions
BR112016015763B1 (en
Inventor
Kroon Henk-Andre
Kawata Hisashi
Shams Naveed
Kawabata Noriko
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53520400&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112016015763(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of BR112016015763B1 publication Critical patent/BR112016015763B1/en
Publication of BR112016015763B8 publication Critical patent/BR112016015763B8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Abstract

preparação farmacêutica, e, método para tratamento ou prevenção de glaucoma ou hipertensão ocular o propósito da presente invenção é descobrir quais compostos dentre o vasto número de compostos de ácido piridilaminocético apresentam uma ação de abaixamento de pressão intraocular notoriamente superior e podem servir como um agente abaixador de pressão intraocular ou como um agente tera-pêutico ou preventivo contra glaucoma ou hipertensão ocular, e descobrir a maneira de administração e/ou de dosagem na qual os compostos desco-bertos concederão um efeito terapêutico ou profilático efetivo quando admi-nistrados aos pacientes (principalmente seres humanos). é fornecida uma preparação farmacêutica para abaixar a pressão intraocular ou para prevenir ou tratar glaucoma ou hipertensão intraocular, a dita preparação farmacêutica contendo 0,0003 a 0,01% (m/v) de (6-{[4-(pirazol-1-il)benzil](piridin-3-ilsulfonil)aminometil}piridin-2-ilamino)acetato de isopropila, ou um sal do mesmo.pharmaceutical preparation, and method for treating or preventing glaucoma or ocular hypertension the purpose of the present invention is to find out which compounds among the vast number of pyridylaminocetic acid compounds have a notably superior intraocular pressure lowering action and can serve as a lowering agent of intraocular pressure or as a therapeutic or preventive agent against glaucoma or ocular hypertension, and discover the method of administration and / or dosage in which the discovered compounds will grant an effective therapeutic or prophylactic effect when administered to patients ( mainly humans). a pharmaceutical preparation is provided to lower intraocular pressure or to prevent or treat glaucoma or intraocular hypertension, said pharmaceutical preparation containing 0.0003 to 0.01% (m / v) of (6 - {[4- (pyrazole-1 -yl) benzyl] (pyridin-3-ylsulfonyl) aminomethyl} pyridin-2-ylamino) isopropyl acetate, or a salt thereof.

BR112016015763A 2014-01-10 2015-01-08 pharmaceutical preparation including pyridylaminocetic acid compound, and, use of the same BR112016015763B8 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461925882P 2014-01-10 2014-01-10
US61/925882 2014-01-10
PCT/JP2015/050366 WO2015105144A1 (en) 2014-01-10 2015-01-08 Pharmaceutical preparation including pyridylamino acetic acid compound

Publications (2)

Publication Number Publication Date
BR112016015763B1 BR112016015763B1 (en) 2020-09-01
BR112016015763B8 true BR112016015763B8 (en) 2020-09-15

Family

ID=53520400

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016015763A BR112016015763B8 (en) 2014-01-10 2015-01-08 pharmaceutical preparation including pyridylaminocetic acid compound, and, use of the same

Country Status (26)

Country Link
US (8) US9415038B2 (en)
EP (3) EP3424503B1 (en)
JP (6) JP5846338B2 (en)
KR (1) KR101824829B1 (en)
CN (2) CN108743587B (en)
AU (1) AU2015205188B2 (en)
BR (1) BR112016015763B8 (en)
CA (1) CA2936026C (en)
CL (1) CL2016001756A1 (en)
DK (1) DK3093018T3 (en)
EA (1) EA031734B1 (en)
ES (2) ES2711091T3 (en)
GE (1) GEP20186917B (en)
HK (1) HK1223036A1 (en)
HU (1) HUE041653T2 (en)
IL (1) IL246447B (en)
MX (1) MX370361B (en)
MY (1) MY163235A (en)
PH (1) PH12016501357B1 (en)
PL (1) PL3093018T3 (en)
PT (1) PT3093018T (en)
SG (1) SG11201605653RA (en)
TR (1) TR201902019T4 (en)
TW (1) TWI598113B (en)
UA (1) UA117506C2 (en)
WO (1) WO2015105144A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2935055C (en) 2014-01-10 2021-08-24 Santen Pharmaceutical Co., Ltd. Pharmaceutical composition containing pyridylaminoacetic acid compound
CN110251516B (en) * 2014-01-10 2022-05-03 参天制药株式会社 Pharmaceutical composition comprising pyridylamino acetic acid compound and polyoxyethylated castor oil
CN108743587B (en) 2014-01-10 2021-04-30 参天制药株式会社 Pharmaceutical preparation containing pyridylamino acetic acid compound
JP5951922B1 (en) * 2014-12-12 2016-07-13 興和株式会社 Aqueous composition
JP6872322B2 (en) * 2015-07-01 2021-05-19 参天製薬株式会社 Depot containing citrate ester
US20180200239A1 (en) 2015-07-09 2018-07-19 Santen Pharmaceutical Co., Ltd. Prophylactic and/or therapeutic agent containing pyridylaminoacetic acid compound
CA3067332A1 (en) 2017-06-16 2018-12-20 The Doshisha Mtor-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof
JPWO2018230713A1 (en) 2017-06-16 2020-04-16 学校法人同志社 Compounds having caspase inhibitory activity, pharmaceuticals containing these compounds for treating or preventing symptoms, disorders or diseases of corneal endothelium and applications thereof
EP3689349A4 (en) * 2017-09-29 2021-06-23 Santen Pharmaceutical Co., Ltd. Drug containing pyridylaminoacetic acid compound
EP3730143A4 (en) 2017-12-21 2021-08-18 Santen Pharmaceutical Co., Ltd. Omidenepag combination
WO2019131901A1 (en) 2017-12-28 2019-07-04 参天製薬株式会社 Pharmaceutical preparation containing pyridyl aminoacetic acid compound
BR112020021845A2 (en) 2018-04-24 2021-02-23 Allergan, Inc. presbyopia treatments

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002356420A (en) * 2001-03-27 2002-12-13 Santen Pharmaceut Co Ltd Table aqueous liquid medicine
CN101970410B (en) 2008-03-12 2014-06-25 宇部兴产株式会社 Pyridylaminoacetic acid compound
SI2415763T1 (en) * 2009-03-30 2016-05-31 Ube Industries, Ltd. Pharmaceutical composition for treating or preventing glaucoma
JP2011057633A (en) 2009-09-11 2011-03-24 Ube Industries Ltd Medicine containing pyridylaminoacetic acid compound
US20120202863A1 (en) * 2011-02-03 2012-08-09 Gerald Horn Compositions and methods for treatment of glaucoma
US20140018350A1 (en) 2012-07-13 2014-01-16 Asahi Glass Co., Ltd. Combination of sulfonamide compound and tafluprost
JP2014019650A (en) * 2012-07-13 2014-02-03 Santen Pharmaceut Co Ltd Combination of sulfonamide compound and tafluprost
CA3099517C (en) * 2012-07-13 2022-04-26 Santen Pharmaceutical Co., Ltd. Combinations comprising a sulfonamide compound for the treatment of glaucoma or ocular hypertension
US9339496B2 (en) * 2012-07-13 2016-05-17 Santen Pharmaceutical Co., Ltd. Composition for treating or preventing glaucoma comprising a sulfonamide compound, and a beta-receptor antagonist
CA2935055C (en) 2014-01-10 2021-08-24 Santen Pharmaceutical Co., Ltd. Pharmaceutical composition containing pyridylaminoacetic acid compound
CN110251516B (en) 2014-01-10 2022-05-03 参天制药株式会社 Pharmaceutical composition comprising pyridylamino acetic acid compound and polyoxyethylated castor oil
CN108743587B (en) 2014-01-10 2021-04-30 参天制药株式会社 Pharmaceutical preparation containing pyridylamino acetic acid compound

Also Published As

Publication number Publication date
TWI598113B (en) 2017-09-11
JP2019108363A (en) 2019-07-04
EA031734B1 (en) 2019-02-28
TR201902019T4 (en) 2019-03-21
PH12016501357A1 (en) 2016-08-15
JP7402922B2 (en) 2023-12-21
IL246447B (en) 2020-06-30
US11197849B2 (en) 2021-12-14
PH12016501357B1 (en) 2016-08-15
GEP20186917B (en) 2018-11-12
CN105899209B (en) 2018-09-11
JP6491588B2 (en) 2019-03-27
UA117506C2 (en) 2018-08-10
JP6785330B2 (en) 2020-11-18
CA2936026A1 (en) 2015-07-16
US20160324838A1 (en) 2016-11-10
SG11201605653RA (en) 2016-08-30
JP2016027060A (en) 2016-02-18
EP3424503A1 (en) 2019-01-09
AU2015205188A1 (en) 2016-07-14
HK1223036A1 (en) 2017-07-21
ES2834334T3 (en) 2021-06-17
JP7087040B2 (en) 2022-06-20
US20240000763A1 (en) 2024-01-04
ES2711091T3 (en) 2019-04-30
JPWO2015105144A1 (en) 2017-03-23
EP3093018B1 (en) 2018-11-28
US20190105310A1 (en) 2019-04-11
PT3093018T (en) 2019-01-10
US10179127B2 (en) 2019-01-15
US10702511B2 (en) 2020-07-07
BR112016015763B1 (en) 2020-09-01
JP5846338B2 (en) 2016-01-20
EP3093018A4 (en) 2017-09-13
WO2015105144A1 (en) 2015-07-16
CN108743587B (en) 2021-04-30
EA201691402A1 (en) 2016-10-31
EP3093018A1 (en) 2016-11-16
JP2022111280A (en) 2022-07-29
PL3093018T3 (en) 2019-05-31
EP3424503B1 (en) 2020-09-02
US9943510B2 (en) 2018-04-17
CL2016001756A1 (en) 2017-05-12
NZ721620A (en) 2021-08-27
JP2024019479A (en) 2024-02-09
TW201609186A (en) 2016-03-16
MY163235A (en) 2017-08-30
AU2015205188B2 (en) 2019-11-14
USRE48183E1 (en) 2020-09-01
KR20160101030A (en) 2016-08-24
EP3750541A1 (en) 2020-12-16
MX370361B (en) 2019-12-10
US11793798B2 (en) 2023-10-24
JP2021006593A (en) 2021-01-21
US20200289483A1 (en) 2020-09-17
US20150196541A1 (en) 2015-07-16
MX2016009063A (en) 2016-09-28
CN108743587A (en) 2018-11-06
IL246447A0 (en) 2016-08-31
US20180169079A1 (en) 2018-06-21
US20220054466A1 (en) 2022-02-24
DK3093018T3 (en) 2019-02-04
US9415038B2 (en) 2016-08-16
CN105899209A (en) 2016-08-24
KR101824829B1 (en) 2018-02-01
HUE041653T2 (en) 2019-05-28
CA2936026C (en) 2022-04-19

Similar Documents

Publication Publication Date Title
BR112016015763B8 (en) pharmaceutical preparation including pyridylaminocetic acid compound, and, use of the same
BR112017010551A2 (en) compound, methods for activating soluble guanylate cyclase, for treating one or more conditions selected from a disease in a patient and for treating a disease or condition, pharmaceutical composition, use of a compound, and, medicament.
BR112017017078A2 (en) compound, pharmaceutical composition, use of a compound, and method to prevent, manage, treat or alleviate a disease.
BR112015029491A2 (en) imidazopyrrolidinone derivatives and their use in the treatment of disease
EA201690069A1 (en) THE USE OF HIGH DOSE PRIDOPIDINE FOR THE TREATMENT OF THE HANTINGTON'S DISEASE
PH12016501394A1 (en) Compounds for treating patients with ros1 mutant cancer cells
MX2021011563A (en) 2,3-dihydro-isoindole-1-on derivative as btk kinase suppressant, and pharmaceutical composition including same.
BR112017017888A2 (en) fluorinated derivatives of tetrahydronaphthyridinyl nonanoic acid derivatives and uses of these
BR112015029512A8 (en) pyrazolopyrrolidine derivatives, their uses, and pharmaceutical composition and combination
BR112013018920A2 (en) nanoparticle compositions, formulations thereof and their uses
BR112014008789A2 (en) prevention and treatment of eye conditions
BRPI0608152A2 (en) eye care formulations
BR112015029401A8 (en) pyrazolo-pyrrolidin-4-one derivatives, their uses, and pharmaceutical composition and combination
BR112015021334A2 (en) Ocular formulations for drug delivery to the posterior segment of the eye
MY183526A (en) Orally administrable pharmaceutical composition for prevention or treatment of dry eye syndrome, comprising rebamipide or prodrug thereof
NZ607103A (en) A water-in-oil type emulsion for treating a disease of the eye
MY199237A (en) Methods of treating ocular conditions
WO2018005801A3 (en) Novel non-systemic tgr5 agonists
WO2018005794A3 (en) Novel non-systemic tgr5 agonists
BR112019007539A2 (en) enteric release formulations of therapeutic agents
CL2020001426A1 (en) Topical ophthalmic composition comprising dobesilic acid to treat diseases of the posterior segment of the eye.
BR112018072647A2 (en) ophthalmic compositions
JP2015522601A5 (en)
BR112015009504A2 (en) rock inhibitors
BR112021025701A2 (en) Isoxazoline parasiticide formulations and methods to treat blepharitis

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/01/2015, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2591 DE 01/09/2020 QUANTO AO TITULO.